Liu Xuan, Zhou Ming, Fang Mujing, Xie Ying, Chen Peiwen, Chen Rirong, Wu Kun, Ye Jianghui, Liu Che, Zhu Huachen, Cheng Tong, Yuan Lunzhi, Zhao Hui, Guan Yi, Xia Ningshao
Clinical Center for Bio-Therapy Zhongshan Hospital Fudan University (Xiamen Branch) Xiamen Fujian China.
State Key Laboratory of Vaccines for Infectious Diseases, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, School of Life Sciences & School of Public Health Xiamen University Xiamen Fujian China.
MedComm (2020). 2024 Jul 19;5(8):e642. doi: 10.1002/mco2.642. eCollection 2024 Aug.
The poor prognosis observed in elderly individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a serious clinical burden and the underlying mechanism is unclear, which necessities detailed investigation of disease characteristics and research for efficient countermeasures. To simulate lethal coronavirus disease 2019 (COVID-19) in senescent human patients, 80-week-old male hamsters are intranasally inoculated with different doses of SARS-CoV-2 Omicron BA.5 variant. Exposure to a low dose of the Omicron BA.5 variant results in early activation of the innate immune response, followed by rapid viral clearance and minimal lung damage. However, a high dose of BA.5 results in impaired interferon signaling, cytokine storm, uncontrolled viral replication, and severe lung injury. To decrease viral load and reverse the deterioration of COVID-19, a new bio-mimic decoy called CoVR-MV is used as a preventive or therapeutic agent. Administration of CoVR-MV as a preventive or therapeutic intervention in the early stages of infection can effectively suppress viral load, regulate the immune response, and rescue animals from death and critical illness. These findings underscore the risk associated with SARS-CoV-2 Omicron BA.5 exposure in senescent hamsters and highlight the importance of early intervention to prevent disease progression.
在感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的老年人中观察到的不良预后仍然是一个严重的临床负担,其潜在机制尚不清楚,这需要对疾病特征进行详细调查并研究有效的应对措施。为了在衰老的人类患者中模拟致命的2019冠状病毒病(COVID-19),对80周龄的雄性仓鼠进行鼻内接种不同剂量的SARS-CoV-2 Omicron BA.5变体。暴露于低剂量的Omicron BA.5变体导致先天免疫反应早期激活,随后病毒迅速清除,肺部损伤最小。然而,高剂量的BA.5会导致干扰素信号传导受损、细胞因子风暴、不受控制的病毒复制和严重的肺损伤。为了降低病毒载量并扭转COVID-19的恶化,一种名为CoVR-MV的新型生物模拟诱饵被用作预防或治疗剂。在感染早期将CoVR-MV作为预防或治疗干预措施进行给药,可以有效抑制病毒载量,调节免疫反应,并使动物免于死亡和重病。这些发现强调了衰老仓鼠暴露于SARS-CoV-2 Omicron BA.5的风险,并突出了早期干预以防止疾病进展的重要性。